Azenta, Inc. · NASDAQ:AZTA

Azenta — Q2 2025 Earnings Presentation

13 slides from Azenta's earnings presentation, May 7, 2025

  1. Slide 1: Fiscal Second Quarter 2025 Financial Results

    Conference Call 1 Fiscal Second Quarter 2025 Financial Results M ay 7 , 2 0 2 5 1 © 2025 Azenta, Inc. • All rights reserved

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that co

  3. Slide 3: Azenta Life Sciences Q2 2025 Financial Overview

    Azenta Life Sciences Q2 2025 Financial Overview Continuing Operations – Quarter Ended March 31, 2025 Balance Sheet and Q2’25 Revenue (YoY) Profitability Capital Allocation • Revenue of $143M, 5% YoY growth on a • Non-GAAP EPS of $0.05 • Strong balance sheet with cash balance reported and 6% on an or

  4. Slide 4: Azenta Operating Performance

    Azenta Operating Performance Continuing Operations – Quarter Ended March 31, 2025 Total Azenta Organic Growth Q1’24 Revenue Growth (YtY) Non-GAAP $ millions $ millions except EPS and percentages Q2'24 Q2'25 YtY Revenue 136 143 5% Az enta | Q2 '2 5 QTD Gross profit 63 68 8% Q1'23 Q1'24 YtY Q2 '2 4 Q2

  5. Slide 5: Q2 2025 Revenue Summary

    Q2 2025 Revenue Summary Organic unless otherwise noted Sample Management Solutions Sample Management Solutions 56% (“SMS”) • Growth of 10% in Sample Repository • $80 million Solutions and 8% in Core Products • 8% YoY reported • Growth of 22% in C&I • 8% YoY organic • Strong quarter for Clinical Stor

  6. Slide 6: Summary Consolidated Balance Sheet

    Summary Consolidated Balance Sheet Quarter Ended March 31, 2025 Balance Sheet Q1’24 Revenue Growth (YtY) Highlights Dec Mar $ millions 2024 2025 QtQ Cash, restricted cash, short term marketable securities 466 330 (135) • B Medical assetsQ1'23 and liabilities are presented Q1'24 YtY as Accounts recei

  7. Slide 7: Summary Consolidated Cash Flow

    Summary Consolidated Cash Flow Quarter Ended March 31, 2025 Cash Flow Q1’24 Revenue Growth (YtY) Highlights $ millions Q2'25 Cash, restricted cash and marketable securities - Beginning 530 • $540M of cash, cash Q1'23equivalents, Q1'24 restrictedYtY cash Net income (40) and marketable securities, inc

  8. Slide 8: Fiscal Year 2025 Guidance

    Fiscal Year 2025 Guidance Continuing Operations Guidance, excluding B Medical Systems Metric FY’2025 Organic Growth: 3% to 5% YoY Revenue Multiomics: LSD Sample Management Solutions: MSD Adjusted 300bps of Adjusted EBITDA EBITDA margin expansion Other Interest Income:$16M - $18M Tax Rate: 27% - 29%

  9. Slide 9: Appendix

    Appendix 9 9 © 2025 Azenta, Inc. • All rights reserved

  10. Slide 10: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation Continuing Operations – Total Azenta $ millions except EPS and percentages $ millions, except EPS Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 FY24 Q1 FY25 Q2 FY25 Revenue 141.7 136.4 144.3 150.8 573.2 147.5 143.4 GAAP gross prof it 61.7 60.7 65.5 69.6 257.5 68.7 65.9 Gross profit

  11. Slide 11: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation Continuing Operations – Segments $ millions except percentages Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 FY24 Q1 FY25 Q2 FY25 Multiomics Revenue 62.7 62.2 63.6 66.0 254.6 66.3 63.5 Gross prof it 28.5 27.7 29.2 30.0 115.4 30.6 27.6 Gross profit margin 45.4% 44.6% 45.9% 45.5% 45.

  12. Slide 12: Net Income to Adjusted EBITDA Reconciliation

    Net Income to Adjusted EBITDA Reconciliation Continuing Operations $ millions Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 FY24 Q1 FY25 Q2 FY25 Net income (15.7) (136.9) (6.6) (5.0) (164.2) (13.3) (40.5) (Income) Loss from discontinued operations, net of tax 8.5 120.7 6.4 4.9 140.5 3.9 22.3 Net income (Loss) f r

  13. Slide 13: Calculation of Non-GAAP Organic Revenue

    Calculation of Non-GAAP Organic Revenue Continuing Operations Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 FY24 Q1 FY25 Q2 FY25 Revenue 4% 2% 4% 6% 4% 4% 5% Acquisitions/divestitures (1%) 0% 0% 0% 0% 0% 0% Currency exchange rates (1%) 0% 1% (0%) 0% (0%) 1% Organic revenue 2% 3% 4% 5% 4% 4% 6% Q1 FY24 Q2 FY24 Q3

Azenta — Q2 2025 Earnings Presentation on 6ix